Clinical Trial Update: Alemtuzumab and CHOP in T-cell Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 trial update investigating alemtuzumab with CHOP in peripheral T-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• alem tumuzumab with CHOP (alemtuzumab)

Snippet

Sponsor: Aarhus University Hospital | Conditions: Lymphoma, T-Cell, Peripheral | Phase 3 | Status: COMPLETED